Recombinant Human EPOR Protein (Catalog#10707-H08H)
Preparation
This antibody was obtained from a rabbit immunized with purified, recombinant Human EPOR (rh EPOR; Catalog#10707-H08H; Met 1-Pro 250; NP_000112.1), and conjugated with horseradish-peroxidase (HRP).
Source
Monoclonal Rabbit IgG Clone #010
Purification
Protein A
Formulation
0.2 μm filtered solution in PBS
Conjugate
HRP
Form
Liquid
Shipping
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Storage
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Protected from prolonged exposure to light. Preservative-Free. Avoid repeated freeze-thaw cycles.
Synonyms: Anti-EPO-R Antibody
Background Information
Full Name
erythropoietin receptor
Description
Erythropoietin (EPO) is the major glycoprotein hormone regulator of mammalian erythropoiesis, and is produced by kidney and liver in an oxygen-dependent manner. The biological effects of EPO are mediated by the specific erythropoietin receptor (EPOR/EPO Receptor) on bone marrow erythroblasts, which transmits signals important for both proliferation and differentiation along the erythroid lineage. EPOR protein is a type â… single-transmembrane cytokine receptor, and belongs to the homodimerizing subclass which functions as ligand-induced or ligand-stabilized homodimers. EPOR signaling prevents neuronal death and ischemic injury. Recent studies have shown that EPO and EPOR protein may be involved in carcinogenesis, angiogenesis, and invasion.
References
Divoky V, et al. (2002) Mouse surviving solely on human erythropoietin receptor (EpoR): model of human EpoR-linked disease. Blood 99(10): 3873-4.
Carruthers SG. (2009) A truncated erythropoietin receptor EPOR-T is associated with hypertension susceptibility. Clin Pharmacol Ther. 86(2): 134-6.
Baltaziak M, et al. (2009) Relationships of P53 and Bak with EPO and EPOR in human colorectal cancer. Anticancer Res. 29(10):4151-6.